These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients. Tak WY; Ryoo BY; Lim HY; Kim DY; Okusaka T; Ikeda M; Hidaka H; Yeon JE; Mizukoshi E; Morimoto M; Lee MA; Yasui K; Kawaguchi Y; Heo J; Morita S; Kim TY; Furuse J; Katayama K; Aramaki T; Hara R; Kimura T; Nakamura O; Kudo M Invest New Drugs; 2018 Dec; 36(6):1072-1084. PubMed ID: 30198057 [TBL] [Abstract][Full Text] [Related]
3. Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study. Bitzer M; Horger M; Giannini EG; Ganten TM; Wörns MA; Siveke JT; Dollinger MM; Gerken G; Scheulen ME; Wege H; Zagonel V; Cillo U; Trevisani F; Santoro A; Montesarchio V; Malek NP; Holzapfel J; Herz T; Ammendola AS; Pegoraro S; Hauns B; Mais A; Lauer UM; Henning SW; Hentsch B J Hepatol; 2016 Aug; 65(2):280-8. PubMed ID: 26952006 [TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma. Streubel G; Schrepfer S; Kallus H; Parnitzke U; Wulff T; Hermann F; Borgmann M; Hamm S Sci Rep; 2021 May; 11(1):9587. PubMed ID: 33953226 [TBL] [Abstract][Full Text] [Related]
5. Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases. Zhang JX; Li DQ; He AR; Motwani M; Vasiliou V; Eswaran J; Mishra L; Kumar R Hepatology; 2012 Jun; 55(6):1840-51. PubMed ID: 22223166 [TBL] [Abstract][Full Text] [Related]
6. Activation of mPTP-dependent mitochondrial apoptosis pathway by a novel pan HDAC inhibitor resminostat in hepatocellular carcinoma cells. Fu M; Shi W; Li Z; Liu H Biochem Biophys Res Commun; 2016 Sep; 477(4):527-533. PubMed ID: 27144317 [TBL] [Abstract][Full Text] [Related]
7. CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. Chang Y; Lee YB; Cho EJ; Lee JH; Yu SJ; Kim YJ; Yoon JH BMC Cancer; 2020 Oct; 20(1):1001. PubMed ID: 33059615 [TBL] [Abstract][Full Text] [Related]
8. Platycodin D reverses histone deacetylase inhibitor resistance in hepatocellular carcinoma cells by repressing ERK1/2-mediated cofilin-1 phosphorylation. Hsu WC; Ramesh S; Shibu MA; Chen MC; Wang TF; Day CH; Chen RJ; Padma VV; Li CC; Tseng YC; Huang CY Phytomedicine; 2021 Feb; 82():153442. PubMed ID: 33412494 [TBL] [Abstract][Full Text] [Related]